How the Microbiome Shapes HPV Infection and Gynecological Cancer Risk

The human body is never truly alone. Trillions of bacteria, fungi and viruses colonize the skin, gut and reproductive tract, forming a living network known as the microbiota. For decades these communities were viewed mainly as passive tenants, but researchers now recognize them as active participants in human physiology, shaping immunity, metabolism and inflammation. When this network falls out of balance, a state called dysbiosis, the consequences can be profound, ranging from metabolic disease to cancer. A new review published in Molecular Biology Reports by Saman Soleimanpour and Atieh Yaghoubi of Mashhad University of Medical Sciences brings together the current evidence on how two microbial ecosystems, the gut and the vagina, interact with human papillomavirus (HPV) and influence the development of gynecological cancers, a group of malignancies that represents a major threat to women’s health worldwide.

HPV is the central player in this story. Persistent infection with high-risk HPV types is the necessary, though not sufficient, condition for most cervical cancers, and the virus has also been implicated in other gynecological malignancies. Yet infection alone rarely causes cancer. Most women clear the virus within a year or two, and only a minority develop persistent infections that progress through cervical intraepithelial neoplasia to invasive carcinoma. This incomplete penetrance has long suggested that cofactors must determine who progresses and who does not. Smoking, immunosuppression and hormonal factors have all been studied, but the review argues that the microbial communities inhabiting the cervicovaginal environment and the gut may be among the most important and most modifiable of these cofactors.

The vaginal microbiota of reproductive-age women is dominated in most cases by Lactobacillus species, particularly Lactobacillus crispatus, which maintain a low pH environment through the production of lactic acid. This acidic milieu inhibits the growth of pathogens and appears to protect against viral acquisition. Researchers classify vaginal communities into community-state types, and the Lactobacillus-poor types, characterized by a diverse array of anaerobic bacteria such as Gardnerella, Prevotella, Atopobium and Sneathia, are collectively described as vaginal dysbiosis or bacterial vaginosis. Multiple systematic reviews and meta-analyses cited in the review, including work by Brusselaers and colleagues and Norenhag and colleagues, converge on the finding that this dysbiotic state is associated with increased odds of HPV infection, reduced clearance of the virus and higher rates of cervical precancerous lesions.

The mechanistic explanations are increasingly detailed. A diverse, Lactobacillus-depleted vaginal microbiota produces enzymes such as sialidase that degrade the protective cervical mucus barrier, potentially exposing epithelial cells to viral particles. Dysbiotic communities also trigger chronic inflammation, activating pattern recognition receptors such as Toll-like receptors on epithelial and immune cells and driving signaling through the MyD88, TRAF6 and NF-κB pathways. The resulting production of pro-inflammatory cytokines, including tumor necrosis factor-alpha and various interleukins, creates a microenvironment rich in reactive oxygen species, which can damage DNA and promote the genomic instability on which HPV’s oncogenic proteins capitalize. Recent work highlighted in the review suggests that Prevotella, a hub organism in dysbiotic cervicovaginal communities, may promote persistent HPV infection and cervical lesions through host NF-κB signaling, linking a specific bacterial genus to a specific oncogenic pathway.

HPV itself, once established, rewires the local immune landscape in ways that favor its own persistence and further microbial disruption. The virus’s E6 and E7 oncoproteins degrade the p53 and retinoblastoma tumor suppressor pathways, driving cell-cycle entry, but they also interfere with innate antiviral responses. Langerhans cells, the dendritic cell subset patrolling the cervical epithelium, are impaired in their ability to present antigen and activate cytotoxic T lymphocytes during persistent infection. The review describes how this immunosuppressive shift alters the commensal population itself, allowing anaerobic organisms to flourish, which in turn sustains inflammation and further impairs viral clearance. The result is a self-reinforcing loop between dysbiosis and viral persistence that can push lesions toward malignancy.

Perhaps the most intriguing dimension of the review is the gut-vaginal axis. The gut microbiota is the body’s largest immune-training organ, and its metabolites, particularly the short-chain fatty acids produced by fiber-fermenting bacteria such as Bifidobacterium and butyrate-producing colon bacteria, circulate systemically and modulate immune tone far beyond the intestinal wall. Short-chain fatty acids signal through receptors such as FFAR2 and influence T-cell differentiation, regulatory immune responses and epithelial integrity. Studies of the estrogen-gut microbiome axis add another layer, showing that gut bacteria regulate circulating estrogen levels, which in turn affect the vaginal epithelium and its susceptibility to infection. Rectal colonization by Lactobacillus species has even been associated with decreased risk of bacterial vaginosis, suggesting that gut organisms can seed or support protective communities in the genital tract.

Beyond cervical cancer, the review surveys evidence linking microbial communities to endometrial and ovarian malignancies. The once-sterile uterus is now known to harbor a distinct microbiome, and studies such as those by Walther-António and colleagues have found that postmenopausal status shapes the composition of the endometrial cancer microbiome, with dysbiotic communities correlating with inflammatory cytokines in endometrial tumors. Organisms such as Atopobium vaginae and Porphyromonas somerae induce pro-inflammatory cytokine expression in endometrial cells, and vaginal detection of Porphyromonas somerae has been reported as indicative of endometrial cancer diagnosis. In ovarian cancer, a case-control study published in Lancet Oncology by Nené and colleagues associated specific cervicovaginal microbiome profiles with BRCA1 mutation carriers at elevated ovarian cancer risk, while prior Chlamydia trachomatis infection, another microbial insult, has been linked to ovarian cancer risk in large independent cohorts.

The review also acknowledges the technical revolution that made this field possible. Culture-independent methods such as 16S rRNA gene sequencing and next-generation sequencing revealed the true diversity of the vaginal and gut ecosystems, while multi-omics approaches that integrate microbiome, metabolome and transcriptome data are now identifying the most powerful predictors of the cervicovaginal microenvironment. One such study found the metabolome to be the top predictor, underscoring that bacterial metabolites, not merely bacterial identities, may drive the cancer-relevant biology. Systems analyses of the HPV-microbiome-biofilm triad represent the next frontier, modeling how these three elements interact dynamically rather than in isolation.

The translational implications are significant. If dysbiosis genuinely promotes HPV persistence and progression, then microbiome-targeted interventions, from probiotic Lactobacillus supplementation to dietary strategies that boost short-chain fatty acid production, could complement vaccination and screening programs. HPV vaccination remains the most powerful preventive tool, and interestingly, recent studies of vaccinated young women suggest the cervicovaginal microbiome still influences breakthrough infection, indicating that microbial factors operate even in the vaccine era. Screening programs could conceivably incorporate microbiome or metabolite markers to stratify women with HPV infections into higher- and lower-risk groups, sparing low-risk patients unnecessary procedures while intensifying surveillance for those with dysbiotic profiles.

The authors are careful to note the limits of the current evidence. Most studies are cross-sectional, capturing microbiome and HPV status at a single time point, which makes it difficult to distinguish cause from consequence; dysbiosis may predispose to persistent infection, or persistent infection may simply create the conditions for dysbiosis. Longitudinal cohorts tracking temporal dynamics of the vaginal microbiota, such as the work of Gajer and Brotman, have begun to address this, showing that instability of the community itself correlates with HPV detection, but mechanistic proof in model systems remains incomplete. The review’s synthesis nonetheless makes a compelling case that the oncobiome, the collective microbial contribution to cancer, is no mirage in gynecological oncology. Understanding how the trillions of microbes in the gut and vagina negotiate with HPV may ultimately open new avenues for preventing one of the most common cancers affecting women worldwide.

Subject of Research: Interaction between gut and vaginal microbiota, HPV infection and gynecological cancer development

Article Title: Oncobiome relation with HPV and Gynecological cancer

Article References: Soleimanpour, S., & Yaghoubi, A. (2026). Oncobiome relation with HPV and Gynecological cancer. Molecular Biology Reports, 53(1), Article 1681. https://doi.org/10.1007/s11033-026-12856-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12856-x

Keywords: oncobiome, HPV, microbiome, dysbiosis, cervical cancer, gynecological cancer, vaginal microbiota, gut microbiota, short-chain fatty acids, endometrial cancer, ovarian cancer, NF-κB